Discovery and verification of gelsolin as a potential biomarker of colorectal adenocarcinoma in a Chinese population: Examining differential protein expression using an iTRAQ labelling-based proteomics approach

Canadian Journal of Gastroenterology

Volumn 26, Issue 1, 2012, Pages 41-47

  Fan, Nai Jun ^a   Gao, Chun Fang ^a   Wang, Chang Song ^a   Lv, Jing Jing ^a   Zhao, Guang ^a   Sheng, Xin Hua ^a   Wang, Xiu Li ^a   Li, Dong Hui ^a   Liu, Qing Yin ^a   Yin, Jian ^a  

^a The 150th Central Hospital of People's Liberation Army   (China)

Author keywords

Biomarker; Colorectal cancer; Gelsolin; Proteomic

Indexed keywords

BIOLOGICAL MARKER; GELSOLIN;

ADULT; ARTICLE; CANCER PATIENT; CHINESE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; WESTERN BLOTTING;

EID: 84863025695     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2012/645218     Document Type: Article

References (33)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin 2010;60:277-300.
2. Hung KE, Yu KH. Proteomic approaches to cancer biomarkers. Gastroenterology 2010;138:46-51.e1.
3. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 1999;17:994-9. (Pubitemid 29474856)
4. Vellaichamy A, Sreekumar A, Strahler JR, et al. Proteomic interrogation of androgen action in prostate cancer cells reveals roles of aminoacyl tRNA synthetases. PLoS One 2009;4:e7075.
5. Smith L, Qutob O, Watson MB, et al. Proteomic identification of putative biomarkers of radiotherapy resistance: A possible role for the 26S proteasome? Neoplasia 2009;11:1194-207.
6. Siu KW, DeSouza LV, Scorilas A, et al. Differential protein expressions in renal cell carcinoma: New biomarker discovery by mass spectrometry. J Proteome Res 2009;8:3797-807.
7. Pernemalm M, De Petris L, Eriksson H, et al. Use of narrow-range peptide IEF to improve detection of lung adenocarcinoma markers in plasma and pleural effusion. Proteomics 2009;9:3414-24.
8. Matta A, Tripathi SC, DeSouza LV, et al. Heterogeneous ribonucleoprotein K is a marker of oral leukoplakia and correlates with poor prognosis of squamous cell carcinoma. Int J Cancer 2009;125:1398-406.
9. Ralhan R, Desouza LV, Matta A, et al. Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry. Mol Cell Proteomics 2008;7:1162-73. (Pubitemid 351943962)
10. Chen Y, Choong LY, Lin Q, et al. Differential expression of novel tyrosine kinase substrates during breast cancer development. Mol Cell Proteomics 2007;6:2072-87.
11. Lee HJ, Na K, Choi EY, Kim KS, Kim H, Paik YK. Simple method for quantitative analysis of N-linked glycoproteins in hepatocellular carcinoma specimens. J Proteome Res 2010;9:308-18.
12. DeSouza L, Diehl G, Rodrigues MJ, et al. Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry. J Proteome Res 2005;4:377-86. (Pubitemid 40548142)
13. Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000;47:251-5. (Pubitemid 30489769)
14. Compton CC, Greene FL. The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin 2004;54:295-308. (Pubitemid 40073988)
15. Litwin M, Mazur AJ, Nowak D, Mannherz HG, Malicka-Blaszkiewicz M. Gelsolin in human colon adenocarcinoma cells with different metastatic potential. Acta Biochim Pol 2009;56:739-43.
16. Noske A, Denkert C, Schober H, et al. Loss of Gelsolin expression in human ovarian carcinomas. Eur J Cancer 2005;41:461-9. (Pubitemid 40187219)
17. Asch HL, Winston JS, Edge SB, Stomper PC, Asch BB. Down-regulation of gelsolin expression in human breast ductal carcinoma in situ with and without invasion. Breast Cancer Res Treat 1999;55:179-88. (Pubitemid 29389580)
18. Gay F, Estornes Y, Saurin JC, et al. In colon carcinogenesis, the cytoskeletal protein gelsolin is down-regulated during the transition from adenoma to carcinoma. Hum Pathol 2008;39:1420-30.
19. Ni XG, Zhou L, Wang GQ, et al. The ubiquitin-proteasome pathway mediates gelsolin protein downregulation in pancreatic cancer. Mol Med 2008;14:582-9.
20. Zamo A, Cecconi D. Proteomic analysis of lymphoid and haematopoietic neoplasms: There's more than biomarker discovery. J Proteomics 2010;73:508-20.
21. Dong Y, Asch HL, Medina D, et al. Concurrent deregulation of gelsolin and cyclin D1 in the majority of human and rodent breast cancers. Int J Cancer 1999;81:930-8. (Pubitemid 29249979)
22. Winston JS, Asch HL, Zhang PJ, Edge SB, Hyland A, Asch BB. Downregulation of gelsolin correlates with the progression to breast carcinoma. Breast Cancer Res Treat 2001;65:11-21. (Pubitemid 32163495)
23. Dosaka-Akita H, Hommura F, Fujita H, et al. Frequent loss of gelsolin expression in non-small cell lung cancers of heavy smokers. Cancer Res 1998;58:322-7. (Pubitemid 28047074)
24. Lee HK, Driscoll D, Asch H, Asch B, Zhang PJ. Downregulated gelsolin expression in hyperplastic and neoplastic lesions of the prostate. Prostate 1999;40:14-9. (Pubitemid 29244490)
25. Rao J, Seligson D, Visapaa H, et al. Tissue microarray analysis of cytoskeletal actin-associated biomarkers gelsolin and E-cadherin in urothelial carcinoma. Cancer 2002;95:1247-57. (Pubitemid 35013059)
26. Visapaa H, Bui M, Huang Y, et al. Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma. Urology 2003;61:845-50. (Pubitemid 36384994)
27. Kim JH, Choi YK, Kwon HJ, Yang HK, Choi JH, Kim DY. Downregulation of gelsolin and retinoic acid receptor beta expression in gastric cancer tissues through histone deacetylase 1. J Gastroenterol Hepatol 2004;19:218-24.
28. Yang J, Tan D, Asch HL, Swede H, Bepler G, Geradts J, Moysich KB. Prognostic significance of gelsolin expression level and variability in non-small cell lung cancer. Lung Cancer 2004;46:29-42. (Pubitemid 39201381)
29. Thor AD, Edgerton SM, Liu S, Moore DH II, Kwiatkowski DJ. Gelsolin as a negative prognostic factor and effector of motility in erbB-2-positive epidermal growth factor receptor-positive breast cancers. Clin Cancer Res 2001;7:2415-24. (Pubitemid 32751644)
30. Shieh DB, Chen IW, Wei TY, et al. Tissue expression of gelsolin in oral carcinogenesis progression and its clinicopathological implications. Oral Oncol 2006;42:599-606.
31. Porter RM, Holme TC, Newman EL, Hopwood D, Wilkinson JM, Cuschieri A. Monoclonal antibodies to cytoskeletal proteins: An immunohistochemical investigation of human colon cancer. J Pathol 1993;170:435-40. (Pubitemid 23253023)
32. Zhang L, Zhou W, Velculescu VE, et al. Gene expression profiles in normal and cancer cells. Science 1997;276:1268-72. (Pubitemid 27227367)
33. Bertucci F, Salas S, Eysteries S, et al. Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene 2004;23:1377-91. (Pubitemid 38406833)